Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724552 | 0.60 | — | — | |
| SCHEMBL15357790 | 0.58 | — | — | |
| Prometon SCHEMBL22999 | 0.56 | KMT2A (0.61) | KCNH3 | |
| Prometon SCHEMBL1517242 | 0.56 | KMT2A (0.61) | KCNH3 | |
| SCHEMBL22334872 | 0.56 | — | — | |
| SCHEMBL2682570 | 0.55 | KMT2A (0.53) | KCNH3 | |
| SCHEMBL29462964 | 0.55 | KMT2A (0.53) | KCNH3 | |
| SCHEMBL19675615 | 0.54 | TRPM8 (0.38) | — | |
| SCHEMBL12411173 | 0.53 | CYP1A2 (0.50) | KCNH3 | |
| SCHEMBL11787532 | 0.52 | MEN1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | KCNH3 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.